Decision Tool for Breast Cancer

Recruiting at 7 trial locations

Overseen By Evan Matros, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Memorial Sloan Kettering Cancer Center

Disqualifiers: Recurrent cancer, Male sex, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

131 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to find out whether it is practical (feasible) to do a larger study looking at the effectiveness of the Breast Reconstruction Decision Aid Tool (RECONJOINT) for breast reconstruction surgery.

Who Is on the Research Team?

Evan Matros, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for individuals over 18 years old who have a genetic predisposition to breast cancer or confirmed diagnosis of ductal carcinoma in situ or invasive cancer. They must be considering post-mastectomy breast reconstruction and have an appointment with a plastic surgery provider.

Inclusion Criteria

I meet the specific requirements to join this study.

I am interested in joining a focus group.

I am a participant in a randomized clinical trial.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive the RECONJOINT decision aid tool in addition to enhanced usual care

Up to 60 days

Follow-up

Participants are monitored for feasibility and effectiveness of the decision aid tool

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• RECONJOINT

Trial Overview

The study is testing the Breast Reconstruction Decision Aid Tool (RECONJOINT) to see if it's helpful for people deciding on breast reconstruction surgery after mastectomy. It aims to determine whether a larger study on this tool would be feasible.

How Is the Trial Designed?

Group I: RECONJOINT/RCT Participants (Patients) Experimental Treatment 1 Intervention

Participants in the RECONJOINT intervention arm will receive the decision aid in addition to enhanced usual care

Group II: RCT Participants (Physicians) Experimental Treatment 1 Intervention

Participating surgeons will be randomized to Enhanced Usual Care or Intervention with a 1:1 ratio

Group III: Focus Group Participants Active Control 1 Intervention

Participants will receive usual care

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+